For the quarter ending 2025-09-30, ORKA has $509,251K in assets. $22,460K in debts. $91,253K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 91,253 | 65,396 | ||
| Marketable securities, current | 257,902 | 263,010 | ||
| Prepaid expenses and other current assets | 6,008 | 3,606 | ||
| Total current assets | 355,163 | 332,012 | ||
| Marketable securities, long-term | 151,763 | 23,053 | ||
| Property and equipment, net | 253 | 174 | ||
| Operating lease right-of-use assets | 1,969 | 2,076 | ||
| Other non-current assets | 103 | 103 | ||
| Total assets | 509,251 | 357,418 | ||
| Accounts payable | 2,208 | 4,664 | ||
| Accrued expenses and other current liabilities | 8,648 | 3,578 | ||
| Operating lease liability, current | 419 | 660 | ||
| Related party common stock warrant liability-Related Party | 9,684 | 3,089 | ||
| Related party accounts payable and other current liabilities-Related Party | 8 | 119 | ||
| Total current liabilities | 20,967 | 12,110 | ||
| Operating lease liability, non-current | 1,493 | 1,666 | ||
| Total liabilities | 22,460 | 13,776 | ||
| Series b non-voting convertible preferred stock, 0.001 par value 251,504 shares authorized as of september 30, 2025 and december 31, 2024 137,138 shares issued and outstanding as of september 30, 2025 and december 31, 2024-Series BNon Voting Convertible Preferred Stock Amount | 2,931 | 2,931 | ||
| Common stock, 0.001 par value 545,000,000 shares authorized as of september 30, 2025 and december 31, 2024 48,384,150 and 37,440,510 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 48 | 37 | ||
| Additional paid-in capital | 643,201 | 469,998 | ||
| Accumulated other comprehensive income (loss) | 185 | -27 | ||
| Accumulated deficit | -159,574 | -129,297 | ||
| Total stockholders equity | 486,791 | 343,642 | ||
| Total liabilities and stockholders equity | 509,251 | 357,418 | ||
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)